Global Partners LP-Ascletis Announces Ultra-Long-Acting Subcutaneous Depot Maintenance Formulation of Small Molecule GLP-1R Agonist ASC30 Demonstrated an Observed Half-Life of 75 Days in Participants with Obesity

-Â Â Â Â Â Â Â Â Â 75-day observed half-life supports once-quarterly administration. -Â Â Â Â Â Â Â Â Â Once-quarterly SQ administration of ASC30 is the most clinically advanced once- quarterly incretin drug and has the potential to address a highlyÂ unmet need as a maintenance therapy for chronic weight management, representing a significant patient population. HONG KONG, Sept. 9, 2025 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces today that ultra-long-acting subcutaneousÂ (SQ)Â d ...